
Gylden’s 2025 Strategic Priorities for Advancing Innovative and Transformative Solutions for Infectious Diseases
Clinical trials planned to begin patient enrollment during 2025 to evaluate Gylden’s T cell Priming (TcP) candidates against Dengue (Phase II) and betacoronaviruses (Phase I-II and Phase II) and planning for study against influenza (Phase I). Versatile …